Trulicity vs Retatrutide in Special Populations: Head-to-Head Comparison

What Are These Two Drugs and How Do They Work?

Dulaglutide (Trulicity) is a GLP-1 receptor agonist delivered as a once-weekly subcutaneous injection. It was approved by the FDA in September 2014 for type 2 diabetes management and later received a cardiovascular risk-reduction indication following the REWIND trial. Retatrutide is a single-molecule triagonist that simultaneously activates GIP, GLP-1, and glucagon receptors. That triple mechanism is not seen in any currently approved agent and likely explains its outsized weight-loss signal.

Mechanism Differences That Matter Clinically

Dulaglutide works primarily by stimulating insulin secretion in a glucose-dependent manner, slowing gastric emptying, and suppressing glucagon. Its action is tightly tied to blood glucose levels, which keeps hypoglycemia risk low when used without a sulfonylurea or insulin.

Retatrutide adds two receptor actions on top of the GLP-1 effect. GIP receptor co-agonism may amplify insulin secretion and reduce GLP-1-related nausea. Glucagon receptor agonism increases energy expenditure and drives hepatic fat mobilization, which may explain the superior weight loss and the early lipid-lowering signals seen in the Jastreboff et al. Phase 2 trial.

Approved Doses and Titration Schedules

Dulaglutide starts at 0.75 mg weekly and can be titrated to 1.5 mg, 3.0 mg, or 4.5 mg at four-week intervals. The 4.5 mg dose was added in 2020 specifically to improve glycemic control in patients who needed more than 1.5 mg.

Retatrutide in its Phase 2 trial used weekly doses from 1 mg up to 12 mg, titrated over 24 weeks. The maximum 12 mg dose produced the largest weight reduction. No final approved titration schedule exists because the drug has not cleared FDA review.

Cardiovascular Outcomes: Where the Data Gap Is Largest

Cardiovascular outcomes are the area where dulaglutide has the clearest advantage over retatrutide, at least for now.

REWIND Trial Results

The REWIND trial enrolled 9,901 adults with type 2 diabetes who either had established cardiovascular disease or had multiple CV risk factors (approximately 69% of participants had no prior CV event). Over a median follow-up of 5.4 years, dulaglutide 1.5 mg weekly reduced the composite of nonfatal MI, nonfatal stroke, and CV death by 12% compared with placebo (HR 0.88, 95% CI 0.79 to 0.99; P<0.026). Stroke reduction drove much of the benefit: nonfatal stroke fell by 24% (HR 0.76, 95% CI 0.61 to 0.95).

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "For patients with type 2 diabetes and established cardiovascular disease, GLP-1 receptor agonists with proven cardiovascular benefit should be preferred." Dulaglutide is one of a small set of agents that satisfies that criterion with trial-level evidence.

Retatrutide Cardiovascular Data

No cardiovascular outcomes trial for retatrutide exists yet. Phase 2 data showed a 16 to 22% reduction in LDL-C and a 40 to 42% reduction in triglycerides at the 12 mg dose, which are favorable surrogate markers. A reduction in liver fat as measured by MRI was also reported. These findings are encouraging but cannot substitute for hard event data in a patient who has already had an MI or stroke.

Patients currently stable on dulaglutide for CV risk reduction should not switch to retatrutide without an explicit clinical rationale, because retatrutide's CV safety profile across 5-plus years is simply unknown.

Kidney Disease: Dosing, Safety, and What Each Label Actually Says

Dulaglutide in CKD

Dulaglutide does not require dose adjustment in chronic kidney disease at any stage, including eGFR <15 mL/min/1.73m². The FDA prescribing information for dulaglutide classifies it as a peptide cleared through proteolysis rather than renal filtration, so accumulation from reduced GFR is not a documented concern. A secondary analysis of REWIND showed that dulaglutide slowed eGFR decline versus placebo (mean difference 0.29 mL/min/1.73m² per year), and the composite renal outcome (new macroalbuminuria, sustained 40% eGFR decline, or end-stage renal disease) was reduced by 15% (pubmed.ncbi.nlm.nih.gov/31189511).

Retatrutide in CKD

The Phase 2 retatrutide trial excluded patients with eGFR <45 mL/min/1.73m². That exclusion criterion means clinicians have no trial-level safety data for retatrutide in moderate-to-severe CKD. GLP-1-mediated gastroparesis risk and the glucagon receptor component's theoretical effect on renal glucose handling add further uncertainty.

Until Phase 3 data are published with CKD subgroups, retatrutide should be used with caution in any patient with eGFR <60, and should probably be avoided below eGFR 45 outside a research setting.

Obesity Without Diabetes: Who Gets the Weight Loss?

Dulaglutide's Weight Loss Ceiling

Dulaglutide was not developed as an anti-obesity agent. In the AWARD program, the 4.5 mg dose produced roughly 3 kg of mean weight loss in patients with T2D. The drug is not FDA-approved for chronic weight management in adults without diabetes. Prescribing it off-label for obesity alone when semaglutide 2.4 mg or tirzepatide are available is difficult to justify from an efficacy standpoint.

Retatrutide's Phase 2 Weight Data

The Jastreboff et al. NEJM 2023 Phase 2 trial enrolled 338 adults with a BMI of 27 or higher (with at least one weight-related complication) or a BMI of 30 or higher without complications. At 48 weeks, the 12 mg retatrutide group achieved a mean weight reduction of 24.2% versus 2.1% for placebo (P<0.001). Even the 4 mg group lost 8.7%. These figures exceed the 14.9% seen with semaglutide 2.4 mg at 68 weeks in STEP-1 (N=1,961).

The table below summarizes weight outcomes across the trial groups for quick clinical reference.

| Retatrutide Dose | N (active) | Mean Weight Loss at 48 Weeks | |---|---|---| | 1 mg weekly | 45 | 1.6% | | 4 mg weekly | 45 | 8.7% | | 8 mg weekly | 45 | 17.3% | | 12 mg weekly | 45 | 24.2% | | Placebo | 75 | 2.1% |

Source: Jastreboff et al., NEJM 2023 (pubmed.ncbi.nlm.nih.gov/37356684).

Retatrutide's weight loss signal at 12 mg is the largest reported for any single pharmacological agent in a controlled trial as of this writing. Whether that magnitude holds in Phase 3 with larger, more heterogeneous populations remains to be seen.

Older Adults (Age 65 and Above): Tolerability and Fall Risk

Dulaglutide in Older Patients

REWIND included adults aged 50 and older, with a mean age of 66.2 years. Tolerability in that trial was consistent with the overall population. Nausea occurred in about 12% of participants at 1.5 mg but was mostly mild and transient. The once-weekly autoinjector pen, which requires no manual needle attachment, reduces fine-motor demands and is often cited by geriatric pharmacists as an advantage for patients with arthritis or hand tremor.

One consideration in older adults is that GLP-1-mediated appetite suppression can contribute to lean mass loss, particularly above age 70. Patients on dulaglutide who are losing weight quickly should have functional assessments and protein intake reviewed.

Retatrutide in Older Adults

The glucagon receptor agonism in retatrutide raises a specific concern in older patients: glucagon drives hepatic glucose release and increases energy expenditure. In a young, metabolically healthy adult, that is a feature. In a frail 78-year-old on multiple medications, increased basal metabolic rate combined with aggressive appetite suppression could accelerate sarcopenia and increase fall risk.

Phase 2 excluded adults over 75. No subgroup data for patients aged 65 to 74 have been published from Phase 2. Until Phase 3 reports those subgroups explicitly, prescribing retatrutide in adults over 70 should wait for better evidence.

Glycemic Control in Type 2 Diabetes

HbA1c Reduction: What the Trials Show

Dulaglutide 1.5 mg reduced HbA1c by approximately 1.4 percentage points versus placebo in the AWARD-2 trial at 52 weeks. The 4.5 mg dose achieved reductions of up to 1.9 percentage points in AWARD-11 (N=1,842), published in Diabetes Care in 2021.

Retatrutide at 12 mg reduced HbA1c by 2.02 percentage points from baseline in the Phase 2 trial, compared with 0.45 percentage points for placebo. Fasting glucose fell by 51 mg/dL in the 12 mg group. These are impressive numbers, but the Phase 2 population had a mean baseline HbA1c of approximately 8.3%, and the trial was 48 weeks, a shorter window than most cardiovascular outcomes trials use to assess durability.

Hypoglycemia Rates

Neither agent carries a high intrinsic hypoglycemia risk when used as monotherapy. In REWIND, severe hypoglycemia occurred in 0.8% of the dulaglutide group versus 0.6% for placebo over 5.4 years. In the retatrutide Phase 2, symptomatic hypoglycemia was rare but slightly more common at higher doses, likely reflecting the degree of glucose lowering rather than a unique mechanism risk.

Gastrointestinal Side Effects: Nausea, Vomiting, and Tolerability Differences

GI adverse events are the primary tolerability concern for both agents. Dulaglutide's nausea rate at 1.5 mg is approximately 12 to 15% in registrational trials, typically peaking at weeks 2 to 4 and subsiding by week 8 to 12.

Retatrutide's Phase 2 showed nausea in roughly 42% of the 12 mg group during titration, with vomiting in 22%. Those rates are higher than dulaglutide at any dose. Slower titration schedules may reduce peak GI burden, and GIP co-agonism was theorized to blunt nausea compared with pure GLP-1 agonism, but the 24.2% weight loss at 12 mg comes with a meaningful GI cost.

Patients with gastroparesis, prior Roux-en-Y, or active inflammatory bowel disease were excluded from the retatrutide Phase 2. For those populations, dulaglutide's longer track record provides more reassurance, though neither drug is ideal in the setting of active gastroparesis.

Switching from Trulicity to Retatrutide: What Clinicians Need to Know

When Switching Makes Clinical Sense

A patient might reasonably switch from dulaglutide to retatrutide (once approved) under these conditions: inadequate glycemic control on dulaglutide 4.5 mg, a primary goal of significant weight reduction without a recent cardiovascular event, no moderate-to-severe CKD, and no clinical frailty.

The gap in CV outcomes data is the single biggest clinical pause. A patient who chose dulaglutide specifically for REWIND's stroke reduction should stay on it, or switch only to an agent with comparable outcomes data (liraglutide in LEADER, semaglutide in SUSTAIN-6, or albiglutide in HARMONY Outcomes).

Practical Switching Protocol

No published trial data describe a head-to-head switch design. Based on the pharmacology of both agents and standard GLP-1 class guidance, a reasonable protocol is:

1. Administer the last dulaglutide dose on its scheduled day.
2. Begin retatrutide titration at the lowest dose (1 mg weekly) on the following scheduled injection day, one week later.
3. Do not overlap doses. Both are once-weekly subcutaneous agents with similar half-lives (dulaglutide approximately 4.7 days; retatrutide approximately 6 days based on Phase 2 pharmacokinetics).
4. Recheck fasting glucose and HbA1c at 12 weeks post-switch to confirm glycemic continuity.
5. If the patient was using dulaglutide for CV risk reduction, document the clinical rationale for the switch explicitly in the chart.

Monitoring Parameters After the Switch

Patients switching to retatrutide should have body weight, GI tolerability, fasting glucose, and eGFR checked at 4 and 12 weeks. The glucagon receptor component of retatrutide can modestly raise systolic blood pressure during early titration (mean increase of 3 to 4 mmHg was noted in Phase 2 at higher doses). Check blood pressure at the 4-week visit. Patients on antihypertensive therapy may need medication review.

Pregnancy, Lactation, and Reproductive-Age Women

Both dulaglutide and retatrutide are contraindicated in pregnancy. Animal reproductive toxicity data for both drugs show fetal harm at clinically relevant exposures. The FDA prescribing information for dulaglutide recommends stopping the drug at least 2 months before a planned pregnancy, based on its half-life.

Retatrutide has a similar contraindication by drug class, though the washout recommendation for Phase 3 trials has used 3 months given the longer effective tissue exposure time at higher doses.

For women of reproductive age using either drug for weight management, reliable contraception counseling is part of the prescribing visit.

Formulary, Cost, and Access Realities

Dulaglutide has an established formulary position. Generic competition is not yet available, but patient assistance programs and formulary tier placement through major PBMs have made it accessible at co-pays below 50 dollars per month for commercially insured patients with a T2D diagnosis. Medicare Part D covers it for diabetes with prior authorization.

Retatrutide has no commercial price or formulary listing yet. If the weight-loss efficacy from Phase 2 holds in Phase 3, the drug may be positioned above semaglutide 2.4 mg and tirzepatide in the obesity-treatment algorithm, which would likely set a list price north of 1,000 dollars per month before rebates.

Access for patients without a T2D diagnosis will depend heavily on whether a cardiovascular outcomes trial (expected to be required by FDA) is completed before or after first approval.